Table 2.
Outcome measures reported in published treatment studies at follow-up (n=20)
| Treatment Type | APS‡ | Negative | Transition | Cognition | Disorganization | General | Total | Global Functionina |
Social Functionina |
Role Functionina |
Quality of Life | Depression | Anxiety | Mania |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cognitive Behavioral Therapy (k=5) | 3 | 2 | 5 | 0 | 0 | 0 | 2 | 5 | 1 | 0 | 3 | 4 | 4 | 0 |
| Cognitive Remediation (k=3) | 1 | 1 | 0 | 3 | 1 | 1 | 1 | 1 | 3 | 2 | 0 | 1 | 0 | 0 |
| Family Therapy (k=1) | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Integrative Psychological | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Therapy (k=1) | ||||||||||||||
| Risperidone + CBT (k=2) | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 2 | 2 | 1 | 1 |
| Antipsychotics (k=3) | 3 | 2 | 2 | 1 | 1 | 2 | 1 | 2 | 0 | 0 | 0 | 2 | 0 | 1 |
| D-serine and Glycine (k=2) | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Omega-3 (k=3) | 2 | 2 | 3 | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 2 | 0 | 1 |
| TOTAL | 75% | 65% | 80% | 30% | 20% | 30% | 50% | 70% | 25% | 15% | 25% | 60% | 25% | 15% |
*
Antipsychotics includes Olanzapine, Amisulpride, Ziprasidone
‡
APS=attenuated psychotic symptoms, negative= negative symptoms, general= general symptoms, total= total symptoms